Events
Priavoid attends the Prion 2022 conference in Göttingen, Germany, between September 13 and 16, with a large delegation. Please, stop by at our booth! We are looking forward to four days of great talks and a lot of exchange with the scientific community.
About Priavoid GmbH:
Priavoid GmbH is a spin-off of Research Center Jülich and Heinrich Heine University Düsseldorf. The company was founded in 2017 and is based in Düsseldorf. It develops novel all-d-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. The most advanced of these is PRI-002 for Alzheimer’s disease. All drug candidates are designed to have an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. The company is privately funded, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner. In addition, the development is significantly supported by the German Federal Agency for Disruptive Innovations, which is funding the PRIMUS-AD phase II study for the drug candidate PRI-002.